Haw-En Wang1, Chih-Lang Lin2, Tai-Long Pan3, Chau-Ting Yeh4. 1. Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C. 2. Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan, R.O.C. 3. Research Center for Chinese Herbal Medicine and Research Center for Food and Cosmetic Safety, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan, R.O.C. chautingy@gmail.com pan@mail.cgu.edu.tw. 4. Liver Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C. chautingy@gmail.com pan@mail.cgu.edu.tw.
Abstract
BACKGROUND/AIM: Our previous cDNA microarray study revealed increased cellular mRNA levels of a panel of genes, including kallikrein-8 (KLK8), after long-term telbivudine treatment in chronic hepatitis B patients. The aim of this study was to verify whether serum protein levels of KLK8, a cancer-related enzyme, are indeed increased after telbivudine treatment. PATIENTS AND METHODS: A total of 83 chronic hepatitis B patients receiving telbivudine for >2 years were retrospectively analyzed. Serum KLK8 protein and estimated glomerular filtration rate (eGFR) changes were compared before and after treatment. RESULTS: Both serum KLK8 protein and eGFR increased significantly after long-term telbivudine treatment (paired t-test: KLK8, p<0.001; eGFR, p=0.001). No direct correlation was found between KLK8 increase and eGFR change. However, eGFR change was positively associated with post-treatment KLK8 levels following adjustment for body height (p<0.001). CONCLUSION: Telbivudine treatment resulted in increased levels of serum KLK8 protein. Furthermore, eGFR increase was associated with body height-adjusted, post-treatment KLK8 levels. Copyright
BACKGROUND/AIM: Our previous cDNA microarray study revealed increased cellular mRNA levels of a panel of genes, including kallikrein-8 (KLK8), after long-term telbivudine treatment in chronic hepatitis B patients. The aim of this study was to verify whether serum protein levels of KLK8, a cancer-related enzyme, are indeed increased after telbivudine treatment. PATIENTS AND METHODS: A total of 83 chronic hepatitis B patients receiving telbivudine for >2 years were retrospectively analyzed. Serum KLK8 protein and estimated glomerular filtration rate (eGFR) changes were compared before and after treatment. RESULTS: Both serum KLK8 protein and eGFR increased significantly after long-term telbivudine treatment (paired t-test: KLK8, p<0.001; eGFR, p=0.001). No direct correlation was found between KLK8 increase and eGFR change. However, eGFR change was positively associated with post-treatment KLK8 levels following adjustment for body height (p<0.001). CONCLUSION: Telbivudine treatment resulted in increased levels of serum KLK8 protein. Furthermore, eGFR increase was associated with body height-adjusted, post-treatment KLK8 levels. Copyright
Authors: H L Y Chan; Y C Chen; E J Gane; S K Sarin; D J Suh; T Piratvisuth; B Prabhakar; S G Hwang; G Choudhuri; R Safadi; T Tanwandee; A Chutaputti; C Yurdaydin; W Bao; C Avila; A Trylesinski Journal: J Viral Hepat Date: 2012-03-15 Impact factor: 3.728